Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | PRNP | P04156 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4094044 | 0.82 | PTGS2 (0.49) | PTGS2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL12940204 | 0.81 | PTGS2 (0.55) | PTGS2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL2299840 | 0.81 | MEN1 (0.56) | PTGS2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL2402202 | 0.81 | ALOX5 (0.48) | PTGS2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL12940202 | 0.80 | PTGS2 (0.58) | PTGS2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL3391480 | 0.80 | PTGS2 (0.51) | PTGS2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL4790812 | 0.79 | PTGS2 (0.52) | PTGS2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL2298170 | 0.77 | PTGS2 (0.50) | PTGS2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL2297483 | 0.77 | PTGS2 (0.50) | PTGS2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL12940201 | 0.77 | PTGS2 (0.56) | PTGS2MEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071797-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2011-12-06 | — | — | US | disclosed |
| US-20090208449-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090208449-A1 | Heterocyclic antiviral compounds | EIF2AK2, HCCS, RTF2 | PTGS2 2072/4885MEN1 4756/4885KMT2A 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.